| 1144 |
Centers for Disease Control and Prevention |
Html |
en |
First Confirmed Cases of Middle East Respiratory SyndromeCoronavirus MERS-CoV Infection in the United States, UpdatedInformation on the Epidemiology of MERS-CoV Infection, and Guidancefor the Public, Clinicians, and Public Health Authorities - May2014 |
Please note: An erratum has been published for this article. To view the erratum, please click here. |
| CDC | 0.540937 |
| CDC guidance | 0.381873 |
| symptom onset | 0.516353 |
| website (http://www.cdc.gov/coronavirus/mers/index.html). | 0.401439 |
| family member | 0.38838 |
| UK | 0.394131 |
| confirmed MERS-CoV infections | 0.376971 |
| contact | 0.447182 |
| East respiratory syndrome | 0.53738 |
| World Health Organization | 0.535869 |
| Indiana State Department | 0.421053 |
| countries | 0.403953 |
| Public health investigations | 0.376392 |
| travelers | 0.392609 |
| laboratory-confirmed MERS-CoV infection | 0.450143 |
| household contacts | 0.381229 |
| illness onset | 0.392315 |
| Arabian Peninsula | 0.630724 |
| United States | 0.815895 |
| MERS-CoV infection control | 0.393084 |
| Cook County | 0.393854 |
| infection control | 0.530809 |
| health-care providers | 0.541022 |
| Saudi Arabia | 0.99195 |
| local health department | 0.543058 |
|
| Middle East | 0.435598 |
| U.S. travelers | 0.390218 |
| respiratory symptoms | 0.419265 |
| infection control precautions | 0.482598 |
| patient | 0.403508 |
| close contact | 0.405619 |
| interim home care | 0.4027 |
| local health | 0.560598 |
| Case count | 0.387694 |
| local health departments | 0.502481 |
| public health | 0.400859 |
| acute respiratory illness | 0.394682 |
| cases | 0.569568 |
| MERS patients | 0.402523 |
| health | 0.588166 |
| travel-associated MERS cases | 0.525448 |
| United Arab Emirates | 0.455867 |
| airborne infection control | 0.383808 |
| MERS-CoV infection | 0.776262 |
| health-care provider | 0.377096 |
| Chicago O'Hare airport | 0.406736 |
| respiratory syndrome coronavirus | 0.541585 |
| home care | 0.416068 |
| Additional CDC guidance | 0.378303 |
|
CLICK HERE |
| 1298 |
Centers for Disease Control and Prevention |
Html |
en |
Assessing and Mitigating the Risks for Polio Outbreaks inPolio-Free Countries - Africa, 2013-2014 |
McKenzie Andre, MD1, Chris G. Wolff, MPH2, Rudolf H. Tangermann, MD2, Paul Chenoweth, ND2, Graham Tallis, MBBS2, Jean Baptiste Kamgang, MS1, Steven G. |
| population immunity risk | 0.594692 |
| supplementary immunization activities | 0.555744 |
| high-risk countries | 0.717019 |
| GPEI partners | 0.626737 |
| polio eradication | 0.697844 |
| WPV importation outbreaks | 0.657881 |
| current risk assessment | 0.582668 |
| polio outbreaks | 0.589012 |
| NPAFP rate | 0.559338 |
| moderate risk category | 0.560534 |
| Equatorial Guinea | 0.800693 |
| surveillance performance indicators | 0.661706 |
| low risk countries | 0.617948 |
| childhood immunity | 0.789919 |
| African countries | 0.766484 |
| Genomic sequence analysis | 0.63186 |
| immunity risk criteria | 0.655411 |
| immunization activities | 0.591077 |
| polio-free countries | 0.593903 |
| routine immunization | 0.586589 |
| high-risk tier | 0.586599 |
| international polio SIA | 0.566819 |
| WPV | 0.691186 |
| moderate risk | 0.604317 |
|
| Global Polio Eradication | 0.596858 |
| national emergency polio | 0.561211 |
| moderate-to-high risk countries | 0.704527 |
| country risk profiles | 0.561655 |
| services puts countries | 0.563227 |
| cases | 0.700872 |
| World Health Organization | 0.614658 |
| polio cases | 0.590735 |
| surveillance indicators | 0.560624 |
| countries | 0.998046 |
| recent WPV cases | 0.57171 |
| acute flaccid paralysis | 0.629561 |
| nationwide polio SIAs | 0.587157 |
| polio vaccination dose | 0.564551 |
| additional WPV spread | 0.556316 |
| AFP surveillance | 0.716559 |
| importation-associated outbreaks | 0.58038 |
| childhood immunity indicators | 0.635609 |
| multicountry outbreaks | 0.616923 |
| WPV outbreaks | 0.686529 |
| risk | 0.851288 |
| outbreaks | 0.832279 |
| childhood immunity risk | 0.596294 |
|
CLICK HERE |
| 4530 |
Centers for Disease Control and Prevention |
Html |
en |
Flu Information for Schools |
CDC recognizes that school administrators, teachers, staff, and parents are concerned about the flu, particularly its effects on children - CDC |
| flu symptoms | 0.623479 |
| different flu virus | 0.661679 |
| flu cough | 0.6616 |
| injectable influenza vaccines | 0.485569 |
| flu infection | 0.607114 |
| flu vaccine | 0.85367 |
| different flu viruses | 0.678402 |
| flu complications | 0.735832 |
| flu vaccines | 0.693942 |
| Vaccine Benefits | 0.475251 |
| influenza virus infection | 0.470135 |
| quadrivalent flu shot | 0.651195 |
| different age groups | 0.50576 |
| young children | 0.465256 |
| flu vaccination | 0.659452 |
| yearly flu vaccine | 0.70489 |
| main flu viruses | 0.675677 |
| spray flu vaccine | 0.693151 |
| influenza vaccine | 0.511033 |
| flu outcomes | 0.660376 |
| influenza vaccines | 0.516379 |
| Influenza vaccine options | 0.510171 |
| flu spreads | 0.614506 |
| antiviral drugs | 0.674143 |
|
| Quadrivalent flu vaccines | 0.65799 |
| seasonal flu vaccine | 0.736071 |
| flu viruses | 0.75104 |
| Different flu shots | 0.652783 |
| flu prevention messages | 0.693944 |
| people | 0.536304 |
| flu | 0.975679 |
| Trivalent flu vaccines | 0.663772 |
| recombinant influenza vaccines | 0.484766 |
| CDC Flu Information | 0.656695 |
| flu share | 0.638561 |
| nasal spray vaccine | 0.520994 |
| flu shot | 0.665454 |
| stomach flu | 0.644897 |
| illness milder | 0.487714 |
| influenza viruses | 0.491284 |
| regular flu shot | 0.650382 |
| high risk | 0.560521 |
| main influenza viruses | 0.485583 |
| different flu | 0.683898 |
| flu season | 0.637533 |
| Cold Versus Flu | 0.670476 |
| Influenza antiviral drugs | 0.491699 |
|
CLICK HERE |
| 4850 |
Centers for Disease Control and Prevention |
Html |
en |
Conjunctivitis: Prevention |
Prevent or reduce the risk of spreading or getting conjunctivitis by following some simple good hygiene steps. |
| Haemophilus influenzae type | 0.489173 |
| hand towels | 0.401294 |
| alcohol-based hand sanitizer | 0.693485 |
| warm water | 0.700892 |
| person’s eye | 0.412941 |
| tips | 0.364163 |
| detergent | 0.34545 |
| non-infected eyes | 0.419762 |
| bed linens | 0.400672 |
| hot water | 0.478286 |
| pink eye | 0.431867 |
| contact lenses | 0.917064 |
| Clean extended wear | 0.506209 |
| eye drops | 0.673085 |
| unwashed hands | 0.467954 |
| ointment | 0.356145 |
| proper handwashing | 0.510314 |
| washcloths | 0.385441 |
| eye | 0.693362 |
| bacterial diseases | 0.396838 |
| eye doctor | 0.495969 |
| contact lens storage | 0.647505 |
| pillows | 0.339036 |
| face makeup | 0.49399 |
| items | 0.40365 |
|
| personal items | 0.401624 |
| soap | 0.421201 |
| washing machine | 0.399103 |
| Clean eyeglasses | 0.53699 |
| CDC’s Clean | 0.532958 |
| eyes | 0.463917 |
| fresh cotton ball | 0.490253 |
| makeup brushes | 0.502727 |
| wet washcloth | 0.41259 |
| cotton balls | 0.402239 |
| good hygiene | 0.416778 |
| website | 0.341464 |
| disposable contact lenses | 0.502103 |
| lens storage cases | 0.652333 |
| conjunctivitis | 0.608772 |
| bacterial infection | 0.397122 |
| Clean Hands Save | 0.742529 |
| people | 0.344104 |
| infected person | 0.565358 |
| eye drop dispenser/bottle | 0.504499 |
| simple steps | 0.420014 |
| Wash pillowcases | 0.469356 |
| bacterial conjunctivitis | 0.496652 |
| risk | 0.343799 |
|
CLICK HERE |
| 8018 |
Centers for Disease Control and Prevention |
Html |
en |
South Africa - GeneXpert's Speedy Diagnosis gets Patients onto TB Treatment Quicker |
CDC partners in South Africa with government and parastatal agencies, private institutions, universities and non-governmental organizations to improve the country’s public health foundation, to prevent transmission of HIV, to provide care and treatment for those who are already infected with HIV, and to strengthen laboratory capacity.
|
| first-line drugs | 0.403138 |
| community health Center | 0.486644 |
| screen people | 0.390668 |
| two-hour drive | 0.404705 |
| Care Association project | 0.465359 |
| huge human investment | 0.463626 |
| effective treatment | 0.403049 |
| extreme weather | 0.405774 |
| nearest laboratory | 0.40101 |
| Disease Control | 0.408031 |
| huge success | 0.388863 |
| GeneXpert machine | 0.390664 |
| community care worker | 0.477524 |
| TB test | 0.682517 |
| CDC TB/HIV Care | 0.532901 |
| test results | 0.386129 |
| South African province | 0.496181 |
| Community Health Centre | 0.501381 |
| cutting-edge diagnostic machine | 0.496769 |
| TB patients | 0.709565 |
| rural setting | 0.407257 |
| community health workers | 0.677183 |
| drug-resistant TB | 0.780867 |
| drug resistance | 0.391569 |
| TB symptoms | 0.644927 |
|
| KZN | 0.360064 |
| entire community | 0.401112 |
| HIV epidemic | 0.397566 |
| TB culture | 0.674321 |
| high levels | 0.486123 |
| opportunistic infections | 0.39891 |
| speedy delivery | 0.390694 |
| rural clinic | 0.409694 |
| pholela community health | 0.626158 |
| long time | 0.396182 |
| TB infection | 0.668857 |
| mountainous terrain | 0.410559 |
| fewer people | 0.38994 |
| sputum sample | 0.487839 |
| TB treatment | 0.643974 |
| Pholela CHC | 0.392646 |
| TB/HIV Care Association | 0.81739 |
| TB cases | 0.66736 |
| PEPFAR | 0.335667 |
| susceptibility results | 0.400463 |
| drug resistant TB | 0.746011 |
| TB | 0.942606 |
| innovative diagnostics | 0.388398 |
| Rapid diagnosis | 0.392144 |
|
CLICK HERE |
| 8713 |
Centers for Disease Control and Prevention |
Html |
en |
Communication with Older Adults - Emergency Preparedness for Older Adults |
null |
| MPEG | 0.378858 |
| search | 0.263099 |
| PDF | 0.261307 |
| PPT | 0.446092 |
|
| DOC | 0.368812 |
| information | 0.262482 |
| different file formats | 0.938484 |
| page | 0.276773 |
|
CLICK HERE |
| 13789 |
Centers for Disease Control and Prevention |
Html |
en |
Use of Serogroup B Meningococcal Vaccines in Adolescents andYoung Adults: Recommendations of the Advisory Committee onImmunization Practices, 2015 |
Recommendations for routine use of vaccines in children, adolescents, and adults are developed by the Advisory Committee on Immunization Practices (ACIP). ACIP is chartered as a federal advisory committee to provide expert external advice and guidance to the Director of the Centers for Disease Control and Prevention (CDC) on use of vaccines and related agents for the control of vaccine-preventable diseases in the civilian population of the United States. Recommendations for routine use of vaccines in children and adolescents are harmonized to the greatest extent possible with recommendations made by the American Academy of Pediatrics (AAP), the American Academy of Family Physicians (AAFP), and the American College of Obstetricians and Gynecologists (ACOG). |
| United States | 0.498488 |
| meningococcal disease cases | 0.220662 |
| meningococcal disease epidemiology | 0.245449 |
| Vaccines Work Group | 0.330495 |
| strains | 0.274668 |
| geometric mean titer | 0.217331 |
| Immunization Practices | 0.201488 |
| safety data | 0.285563 |
| composite response | 0.311309 |
| college students | 0.269873 |
| meningococcal conjugate vaccine | 0.245785 |
| meningococcal disease incidence | 0.24507 |
| Practices Meningococcal Vaccines | 0.278547 |
| clinical trials | 0.694644 |
| ACIP Meningococcal Vaccines | 0.477545 |
| meningococcal strains | 0.218758 |
|
| selected meningococcal serogroup | 0.316088 |
| MenB-FHbp | 0.220662 |
| adolescents | 0.22031 |
| meningococcal conjugate vaccines | 0.313582 |
| Serogroup B Meningococcal | 0.306087 |
| unpublished data | 0.498631 |
| adverse events | 0.415493 |
| MenB vaccines | 0.813867 |
| vaccine effectiveness | 0.223525 |
| meningococcal disease | 0.969073 |
| serogroup | 0.434871 |
| young adults | 0.629858 |
| MenB-4C | 0.209315 |
| mean titer ratio | 0.218095 |
| Meningococcal Vaccines Work | 0.427287 |
|
CLICK HERE |
| 14225 |
Centers for Disease Control and Prevention |
Html |
en |
How to Protect Yourself |
Information on Zika virus. Provided by the U.S. Centers for Disease Control and Prevention. |
| condoms | 0.376093 |
| Zika infection | 0.576066 |
| United States | 0.456524 |
| infected mosquitoes | 0.485193 |
| Zika virus | 0.588512 |
| domestic travel | 0.450726 |
| prenatal care visit | 0.547605 |
| Zika | 0.93362 |
| muscle pain | 0.437865 |
| pregnant women | 0.807915 |
| yellow cautionary areas | 0.578507 |
| pregnant woman | 0.511199 |
| birth defect | 0.474212 |
| talk | 0.386409 |
| Routine testing | 0.432044 |
| CDC’s guidance | 0.452146 |
| red eyes | 0.443605 |
| abnormalities | 0.330274 |
| start | 0.358903 |
| joint pain | 0.438764 |
| practice safe sex | 0.572818 |
|
| steps | 0.501513 |
| bites | 0.417453 |
| prenatal care | 0.550117 |
| individual situation | 0.449617 |
| symptoms | 0.434638 |
| doctor | 0.423764 |
| regular prenatal care | 0.549636 |
| rash | 0.332349 |
| vaccine | 0.332439 |
| healthcare provider | 0.595516 |
| Zika virus transmission | 0.582666 |
| additional rounds | 0.443829 |
| risk | 0.397607 |
| information | 0.329618 |
| time | 0.392779 |
| headache | 0.329039 |
| travel | 0.476507 |
| fetal brain defects | 0.614827 |
| entire pregnancy | 0.437003 |
| fetus | 0.381874 |
| special precautions | 0.461052 |
|
CLICK HERE |
| 15772 |
Centers for Disease Control and Prevention |
Video |
en |
Take Pride in Your Job: Fall Protection |
NIOSH Publication No. 2009--108d http://www.cdc.gov/niosh/
This video encourages oil and gas extraction workers to use fall protection and never be "un-clipped" and thus vulnerable when at height. The video features oil and gas extraction workers talking about their use of fall protection and sharing their personal stories about why fall protection should always be worn when working at height. The purpose of the video is to raise awareness of fall injuries in this industry and to provide information about the use, proper fit, and inspection of fall protection. This video is designed to be used in pre-shift or weekly safety meetings. |
|
|
CLICK HERE |
| 16000 |
Centers for Disease Control and Prevention |
Html |
en |
Diagnostic Tests for Zika Virus |
Information on Zika virus. Provided by the U.S. Centers for Disease Control and Prevention. |
| NAT | 0.443641 |
| symptomatic non-pregnant individuals | 0.382414 |
| Zika virus | 0.951841 |
| IgM testing | 0.230247 |
| similar clinical illness | 0.23969 |
| Zika virus infection | 0.596289 |
| Trioplex Real-Time RT-PCR | 0.242418 |
| IgM serology | 0.531317 |
| NAT testing | 0.289755 |
| recent possible exposure | 0.244082 |
| testing algorithm | 0.334798 |
| symptomatic patient | 0.26029 |
| non-negative serology results | 0.2547 |
| RNA NAT | 0.249129 |
| symptomatic pregnant women | 0.849866 |
| congenital Zika virus | 0.357475 |
|
| Zika virus exposure | 0.293079 |
| NAT negative samples | 0.277609 |
| ongoing possible exposure | 0.241374 |
| prenatal ultrasound findings | 0.336492 |
| Zika virus NAT | 0.332057 |
| negative NAT result | 0.290087 |
| symptomatic persons | 0.248191 |
| IgM levels | 0.226482 |
| possible exposure | 0.414613 |
| physician-patient decision-making model | 0.22675 |
| PRNT Reference Center | 0.213273 |
| Zika virus-specific IgM | 0.290089 |
| asymptomatic pregnant women | 0.522362 |
| nucleic acid testing | 0.233892 |
| public health laboratory | 0.213416 |
|
CLICK HERE |